Several species of African trypanosomes cause fatal disease in livestock, but most cannot infect humans due to innate trypanosome lytic factors (TLFs). Human TLFs are pore forming highdensity lipoprotein (HDL) particles that contain apolipoprotein L-I (apoL-I) the trypanolytic component, and haptoglobin-related protein (Hpr), which binds free hemoglobin (Hb) in blood and facilitates the uptake of TLF via a trypanosome haptoglobinhemoglobin receptor. The human-infective Trypanosoma brucei rhodesiense escapes lysis by TLF by expression of serum resistanceassociated (SRA) protein, which binds and neutralizes apoL-I. Unlike humans, baboons are not susceptible to infection by T. b. rhodesiense due to previously unidentified serum factors. Here, we show that baboons have a TLF complex that contains orthologs of Hpr and apoL-I and that full-length baboon apoL-I confers trypanolytic activity to mice and when expressed together with baboon Hpr and human apoA-I, provides protection against both animal infective and the human-infective T. brucei rhodesiense in vivo. We further define two critical lysines near the C terminus of baboon apoL-1 that are necessary and sufficient to prevent binding to SRA and thereby confer resistance to human-infective trypanosomes. These findings form the basis for the creation of TLF transgenic livestock that would be resistant to animal and human-infective trypanosomes, which would result in the reduction of disease and the zoonotic transmission of human infective trypanosomes.
A frican trypanosomes are extracellular protozoan parasites that are transmitted between mammalian hosts by the bite of an infected tsetse fly. Human African Trypanosomiasis (HAT) or sleeping sickness is caused by T. brucei rhodesiense or T. brucei gambiense. The two subspecies are geographically distinct, the separation can be approximated to T. b. gambiense present west of the Great Rift Valley and T. b. rhodesiense to the east. Trypanosomiasis in livestock has a significant impact on agricultural productivity and is caused mainly by T. congolense, T. vivax, T. brucei brucei and T. b. rhodesiense (1) . Livestock are a major reservoir of HAT caused by T. b rhodesiense (2) . T. b. brucei does not infect humans or a subset of catarrhine primates due to innate resistance mediated by trypanolytic factors (TLFs) present in serum (3) (4) (5) .
Human TLFs consist of two minor HDL subfractions (TLF1 and TLF2), characterized by the presence of haptoglobin-related protein (Hpr) and apoliporotein L-I (apoL-I) (3, (6) (7) (8) . TLFs are endocytosed by trypanosomes and within the acidic lysosome, apoL-I is activated to form membrane pores, resulting in ion disregulation that leads to osmotic imbalance, parasite swelling and lysis (9, 10) . Although both human apoL-I and Hpr have been proposed to kill trypanosomes independently in vitro (10, 11) , only transgenic mice producing human apoL-I are protected from T. b. brucei infection in vivo (12) , whereas mice producing human Hpr are unprotected (12, 13) . However, Hpr increases the specific activity of human TLF in vitro and in vivo (11, 12) , which is in part due to the binding of Hpr-Hb to a haptoglobinhemoglobin receptor on the trypanosome cell surface, leading to an increased uptake of apoL-I (14, 15) .
The resistance to human serum by T. b. rhodesiense is due to the production of the SRA protein, which stoichiometrically binds apoL-I and either neutralizes its activity directly in the lysosome (7) and/or reroutes its trafficking away from the lysosome (16) . The mechanism of resistance in T. b. gambiense is unknown but does not involve SRA. In contrast to humans and gorillas; serum from baboons, sooty mangabeys and mandrills can kill both T. b. brucei and T. b. rhodesiense (3, 17) , via a trypanolytic component found within HDLs. In this study we aimed to elucidate the molecular details of a non-human primate trypanosome lytic factor and the mechanism by which it kills the human infective parasite, T. b. rhodesiense.
Results

Purification, Identification, Cloning, and Expression of Baboon TLF
Components. To understand the mechanism of killing of T. b. rhodesiense by these non-human primates, we concentrated on baboon TLF due to the availability of tissues and plasma from primate centers in the U.S. and the availability of a partial baboon genome sequence. Highly enriched TLF was obtained from baboon HDLs using affinity chromatography with an anti-human Hp antibody, previously used to immunoprecipitate baboon TLF (3) ( Table S1 ). The components of baboon TLF included the canonical HDL apolipoprotein, apoA-I and at least 5 other polypeptides (Fig. 1A ), which were identified by tandem mass spectrometry analysis of tryptic peptides (Table S2 ). The polypeptides identified were: (i) Hpr or Hp dimer (60 kDa), Hpr or Hp ␤ chains (50 kDa), and Hpr or Hp ␣ chains (13 kDa); no peptides were identified that distinguished Hpr from Hp, which are Ϸ96% identical (3). (ii) Two other polypeptides of Ϸ53 kDa did not match any sequences in the database, so peptide sequences were obtained de novo from the mass spectrometry data using Peaks Online (www.bioinformaticssolutions.com/ peaksonline). The two polypeptides contained 4 peptide sequences that were homologous to the human apoL gene family; in addition, one peptide was unique to apoL-I compared to other apoL paralogs. These data indicated that baboon TLF contains an apoL-I ortholog in addition to Hpr.
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full-length cDNAs from baboon liver. The predicted protein product of the baboon apoL-I gene is a 40-kDa mature protein with an additional N-terminal signal peptide that is removed. Baboon apoL-I is 58% identical to the human protein and contains a 14-aa deletion and a 6-aa insertion (Fig. 1B) . There are two potential glycosylation sites in baboon apoL-I compared to a single site in human apoL-I. Baboon Hpr is a predicted 39-kDa mature protein including the N-terminal signal peptide, which remains attached to the secreted protein. It is 94% identical to human Hpr with two extra potential glycosylation sites (3).
To determine the potential roles of baboon apoL-I and baboon Hpr in the killing of human-infective trypanosomes, hydrodynamic gene delivery (HGD) of expression constructs was used in mice (Fig. S1 ). HGD was recently used to dissect the roles of human TLF components leading to the conclusion that human Hpr, apoL-I and apoA-I are required to produce TLF with comparable lytic activity to human TLF (12) . Human apoA-I is 95% identical to baboon apoA-I (compared to Ϸ65% identity between baboon and murine apoA-I), therefore human apoA-I transgenic mice Tg(APOAI) were used as a background strain. Three days after HGD of baboon Hpr and/or apoL-I, HDLs were prepared from plasma and probed for the presence of baboon TLF proteins by Western blot analysis ( Fig. 2 A and  B) . In the absence of Hpr, baboon apoL-I was broadly distributed throughout the apoA-I containing HDL fractions (blue mouse), whereas in dual transgene expressing mice, baboon apoL-I and Hpr cosegregated into to a relatively high molecular mass HDL subfraction (red mouse). Baboon apoL-I migrates as a doublet near 55 kDa whether expressed in baboons or mice; this higher than expected apparent molecular mass may arise from glycosylation at one or both of the potential N-linked glycosylation sites.
Evaluation of the Lytic Capacity of Baboon TLF Components in Vitro.
Having confirmed that HGD provided a valid model for synthesising baboon TLF components, we tested sera and purified HDLs for their capacity to kill human serum-resistant trypanosomes (T. brucei 427-SRA) in vitro. Human serum, purified human HDLs or HGD mice expressing human TLF does not kill these trypanosomes in the standard 2.5-h assay (12) (18). However, the purified HDL from mice expressing baboon apoL-I and Hpr killed, whereas there was no measurable activity in HDLs from mice expressing either baboon apoL-I or Hpr singly. Importantly, the lytic activity of the HDL containing both baboon apoL-I and Hpr was inhibited by ammonium chloride, which is a lysosmotrophic agent that reverses the acidification of internal organelles and thereby blocks TLF activity (Fig. S2) . To observe any trace of activity in the sera from the different HGD mice, the incubation time of the assay was increased from 2.5 to17 h and sera concentration was titered from 0.1-10% to reveal any differences in specific activity. Sera from mice containing baboon apoL-I killed trypanosomes at concentrations of 5% or more, whereas sera from mice expressing Hpr had no activity. Sera from mice expressing both baboon apoL-I and Hpr had by far the greatest specific activity and killed at 0.1% (Fig. 2C) . These data show that the baboon apoL-I ortholog is responsible for the killing of human infective trypanosomes and that Hpr enhances this activity.
Evaluation of the Lytic Capacity of Baboon TLF Components in Vivo.
Next, we tested the ability of baboon apoL-I in combination with baboon Hpr to protect against trypanosome infection in vivo. When Tg(APOAI) mice were infected with human-infective T. b. rhodesiense (KETRI 243), the combination of baboon apoL-I and Hpr expression provided complete protection. Expression of baboon apoL-I alone resulted in an extension of the median survival time by nine days compared to control mice with vector alone (Fig. 3A) . This shows that Hpr can increase the lytic capacity of apoL-I. In contrast, the expression of baboon apoL-I and Hpr did not provide protection in the congenic strain of mice (C57BL6), indicating that human apoA-I increased the potency (likely stability) of baboon TLF against T. b. rhodesiense (Fig. 3B) .
We then evaluated human serum-resistant trypanosomes (T. brucei 427-SRA), which constitutively express SRA and have a faster doubling time than KETRI 243; control mice died within 4-7 days. Mice expressing apoL-I alone were completely protected, whereas 4 out of 5 mice expressing baboon apoL-I and Hpr were protected (Fig. 4A) . The one mouse that developed a parasitemia did so only on day 26 after infection, perhaps due to decreasing levels of apoL-I and Hpr in plasma with time after HGD. It is also possible that the trypanosomes survived in tissue spaces where the HDL (and therefore TLF) concentration is reported to be 25% of that in plasma (19) and subsequently recrudesced as serum TLF declined. We then tested the ability of baboon apoL-I and Hpr to protect against infection with T. congolense, to evaluate the possibility of using baboon TLF to generate transgenic livestock with resistance to other animal infective trypanosomes. T. congolense and T. vivax both produce relapsing and debilitating parasitemias in animals. In control mice, infection with T. congolense characteristically resulted in an initial wave of blood parasitemia, which was detectable by day 5 and declined by days 15-20 (Fig. 4B) . When baboon apoL-I was expressed in Tg(APOAI) mice there was a delayed parasitemia detectable four days after the control, whereas when both baboon apoL-I and Hpr were expressed in Tg(APOAI) mice there was no detectable parasitemia ( Fig. 4B ; limit of detection 5 ϫ 10 5 /mL).
Overall these data suggest that both baboon TLF components may be required to maximally protect transgenic animals from T. congolense and T. b. rhodesiense infection; although sustained production of apoL-I from a stable transgenic may be sufficient. A homologue of the T. brucei Hp/Hpr-Hb receptor, which enhances the uptake of human Hpr-Hb-associated TLF complexes has been identified in T. congolense and T. b. rhodesiense (14) . This Hp/Hpr-Hb receptor likely facilitates the rapid uptake and accumulation of baboon TLF by these trypanosomes in vivo before blood levels of TLF significantly decline.
Delineation of the SRA Antagonist Domain in Baboon apoL-I. We have shown that transgenic expression of human apoL-I does not protect against T. b. rhodesiense, whereas expression of baboon apoL-I does, and that transgenic protection is lost when the C-terminal domain, which interacts with SRA is deleted (12) . Therefore, a series of apoL-I transgenes with human/baboon chimeric C-terminal domains were made (Fig. 5A ) and expressed in mice using HGD. Chimeras 1 to 3 protected mice from trypanosomes that expressed SRA whereas chimera 4 did not (Fig. 5B) . The difference between chimeras 3 and 4 was just three residues, and within these 3 residues there are two asparagines in human apoL-I versus two lysines in baboon. A chimeric transgene consisting of human apoL-I in which only these two asparagines were substituted with lysines was sufficient to provide complete protection against trypanosomes expressing SRA (Fig. 5A) . The ability of the various apoL-I chimeras to kill human serum-resistant trypanosomes mirrored the lack of binding to recombinant SRA in vitro (Fig. 5C) . Furthermore, human HDL bound SRA, whereas baboon HDL did not (Fig. S3) .
Discussion
We have presented the discovery of a baboon apoL-I ortholog that can transgenically provide protection against animal infective trypanosomes and human serum-resistant T. b. rhodesiense. The ability to kill parasites that express the serum resistance- associated protein (SRA), is due to two lysines in the C terminus of baboon apoL-I, which prevent the binding of apoL-I to SRA.
Lack of binding to SRA may be due to the oligomerization state and/or the charge of the C terminus of baboon apoL-I. The last 30 aa of both human and baboon C-termini are predicted by modeling to form an amphipathic ␣ helix, wherein the hydrophobic amino acid face may be buried into the HDL lipid and the hydrophilic face will be exposed. The C terminus of baboon apoL-I is more basic with a calculated pI of 8.8 and thus will be positively charged and may repel binding to SRA, whereas that of human apoL-I is more acidic with a calculated pI of 4.8, which would be close to neutral in the lysosome. Alternatively modeling predicts that the amphipathic helix, which contains four heptad repeats ([abcdegf] where a and d are hydrophobic residues) may form a coil coiled, which is a superhelical structure stabilised by hydrophobic residues buried in the center. The baboon C terminus and the protective chimeras of apoL-I are predicted to form a three stranded coiled coil, whereas the human C terminus may form a two stranded coiled coil. It is plausible that trimerization of the baboon C-termini coupled with the surface positive charge prevents the interactions of apoL-I with SRA.
Previous studies revealed that C-terminally truncated human apoL-I, which is unable to bind to SRA, can kill human serum-resistant trypanosomes when conjugated to a single domain antibody that binds to a carbohydrate moiety on the surface coat of trypanosomes (20) . Given that the antibody would bind to the entire surface of the trypanosomes (Ϸ10 7 molecules) and be rapidly and constantly cleared from the surface by hydrodynamic forces and endocytosis (21), we surmise that supraphysiological quantities of apoL-I would be delivered to the parasite lysosome by this route. In contrast, mice that express truncated human apoL-I, even when coexpressed with human Hpr and apoA-I, do not have any significant trypanolytic activity; likely due to the delivery of physiological concentrations of apoL-I via Hp-Hb receptor (Ϸ200-400 receptors) and scavenger receptor mediated endocytosis from the flagellar pocket (12) . Thus, truncated human apoL-I can best be described as a hypomorph, it has partial activity under certain conditions, but requires the C terminus for full activity in vivo. In support of this interpretation, a recent analysis of the apoL gene family evolution in primates concluded that the C terminus must be essential otherwise antagonism by T. b. rhodesiense and other pathogens would have resulted in deletion of this domain (22) . Instead, parts of the C terminus have undergone positive selection, in this instance a modification to change the charge, presumably to evade neutralization mechanisms elaborated by pathogens while maintaining the critical function of the C terminus, which in our opinion is likely to facilitate proximity to and binding to the target membrane.
Taken together, our findings describe the identification of an apoL-I homolog from baboons that can transgenically protect mice from animal-infective trypanosomes and the human pathogen T. b. rhodesiense. These findings provide a compelling rationale for creating transgenic livestock expressing baboon apoL-I. The importance of trypanosome-resistant cattle is not solely for livestock productivity. In East Africa, Human African Trypanosomiasis is caused by T. b. rhodesiense and is a zoonotic disease with cattle as the major reservoir hosts (2) . In West and Central Africa T. b gambiense is prevalent but is not found in cattle. Furthermore, some baboons (Papio papio) are not infected with T. b gambiense, whereas other baboons (Papio hamadryas sp., used in this study) can be infected with T. b gambiense but eventually clear the parasitemia after a few months (23) . Whether this is due to baboon TLF or not will likely require the generation of sustained stable transgenic expression of TLF components. We conclude from the work in this investigation that the generation of resistant transgenic cattle has the potential to improve livestock productivity and reduce transmission of Human African Trypanosomiasis caused by T. b. rhodesiense.
Materials and Methods
Preparation and Mass Spectrometry Analysis of Baboon TLF. Total baboon lipoproteins (Ϸ100 mg of protein) were fractionated on a 100-mL superose-6 gel filtration column. Trypanolytic fractions were identified as described in ref. 3 , pooled and concentrated. HDL was further separated from serum proteins using a high-resolution superdex-200 gel filtration column. To obtain highly purified TLF, lytic fractions were applied to a 1-mL polyclonal antihuman haptoglobin IgG (Sigma) coupled NHS Sepharose column (GE lifesciences). The bound fraction, containing TLF was eluted using 0.1M TEA, pH 11.5 and neutralized with 1M Tris pH5.0. Specific activity was assessed at each stage using the standard trypanosome lysis assay (18) (Table S1 ). TLF samples, separated by 4 -20% SDS PAGE were silver stained and proteins were analyzed by Q-TOF tandem mass spectrometry (Protein Analysis facility, NYULMC, U.S. and FingerPrints Protein Analysis Facility, University of Dundee, U.K.). Proteins were identified by database matching (MASCOT) or in the case of baboon were infected with 5,000 T. congolense (STIB68Q) and blood parasitaemia was monitored (5 ϫ 10 5 parasites/mL of blood ϭ limit of detection). The data are presented as mean Ϯ SD. apoL-I:Hpr and apoL-I mice were significantly different from vector controls (days 0 -21) and apoL-I mice were significantly different from vector controls during days 0 -9 ( * , P ϭ 0.0208, ** , P ϭ 0.0015) (two-way ANOVA). apoL-I, by de novo sequence assignment (PEAKSOnline (18); peptide sequences are shown in Table S2 ).
Cloning of the Baboon apoL-I and Baboon Hpr Genes. Baboon (Papio hamadryas sp.) liver biopsies were obtained from the Southwest National Primate Research Center, San Antonio Texas. Total RNA was extracted from a 0.5g biopsy of baboon liver using TRIzol reagent (Invitrogen), according the manufacturers instructions. 5ЈRACE was performed using the 5Ј/3Ј RACE kit 2 nd generation (Roche) using 1 g of total RNA. Primer sequence designs were based on the human apoL-I gene sequence, with alterations consistent with the baboon apoL-I peptide sequences obtained from mass spectrometry: SP1 (cDNA synthesis primer): CTCCAGCTCCTGAGCCAC and SP2 (gene specific reverse PCR primer): GCTGAGACTGGCTCAGTGAC.
The 5Ј apoL-I cDNA was cloned and the sequence used to query the National Center for Biotechnology Information nucleotide database. The top hits were a macaca mulatta BAC clone (gb͉AC200580) followed by the human apoL-I gene. The macaque sequence was aligned with the human apoL-I gene to reveal a near identical sequence in the 3ЈUTR, which was used to design a reverse primer for RT PCR of the entire baboon apoL-I coding sequence: Forward: CTCGAGGCCACCATGGAGGGAGCTGCTTTGCTGAGAC. [Unique Xho-I site (italic) and kozak sequence (bold) were added]. Reverse: GGTGGT-TGCCCTGCCCTGTGG. A baboon Hpr gene fragment was cloned previously by RT-PCR (3). The remaining 5Ј end was obtained by 5Ј RACE using the following specific internal primer: Reverse: GCATAATCCTTTGAGGGTAGGCAG.
Expression of Baboon apoL-I and Baboon Hpr Genes in Mice Using Hydrodynamic
Gene Delivery (HGD). Baboon apoL-I, Hpr or both baboon apoL-I and Hpr coding sequences were inserted into a mammalian expression vector (pRG977, Regeneron Pharmaceuticals, Tarrytown, NY) as shown in Fig. S1 . All constructs contain a ␤-lactamase gene and an origin of replication to allow for propagation in bacteria. Each apoL-I or Hpr coding sequence is ligated into a multiple cloning site, positioned between a ␤-globin intron (5Ј of coding sequence) and an SV40 poly(A) signal sequence (3Ј of coding sequence) to increase the stability and cytoplasmic translocation of the encoded mRNA transcripts in mammalian cells (Fig. S1) . To allow the independent expression of baboon apoL-I and baboon Hpr genes in the same mouse cell, a dual expression construct was made in which each gene has a separate ubiquitin promoter, ␤-globin intron and SV40 poly(A) signal sequence (Fig. S1 ). Mice were injected iv. with 50 g or 100 g of plasmid for single and dual expression constructs respectively. Plasmids were administered in 2.0 -2.8 mL of saline, which allows for secretion of human apoL-I and Hpr from mouse hepatocytes into blood within 24 h as described (12, 24) . ApoL-I gene chimeras were produced using overlap extension PCR, exactly as described in ref. 25 . C57BL/ 6-Tg(APOAI)1Rub/J, congenic C57BL/6 and Swiss-Webster mice were used for all in vivo experiments. All animal experiments were approved by the IACUC at New York University Medical Center, which has a currently approved Animal Welfare Assurance Agreement (no. A3435-01) with the National Institutes of Health Office for Protection from Research Risks.
Antibodies used in Western Blot Analysis. On day 3 after injection of plasmid, the presence of baboon proteins in blood was verified by Western blot. The antibodies used were as follows: polyclonal rabbit anti-haptoglobin (Sigma, 1:20,000), polyclonal sheep anti-human apoA-I (1:10, 000; AbD Serotec) and polyclonal anti-human apoL-I (1:10,000, ProteinTech.). The anti-baboon apoL-I polyclonal (1:500, Regeneron Pharmaceuticals) was obtained from mice immunized intradermally with the baboon apoL-I expression construct used in HGD experiments. Secondary antibodies were horse radish peroxidase conjugated and used as follows: anti-Rabbit IgG (1:20,000; Promega); anti-sheep IgG (1:10,000, Roche) and anti-mouse IgG Fc␥ (1:5,000, Jackson Immuno Research Labs.) Trypanosome Strains. On day 3 after injection of plasmid, the mice were infected with 5,000 trypanosomes. The following trypanosomes were used: human serum-sensitive T. b. brucei Lister 427-derived cell line, the human serum-resistant strain T. b. brucei 427-derived cell line (427-SRA) and T. b. rhodesiense KETRI 243, isolated from a human patient in Busoga, Uganda. T. congolense (STIB 68-Q) came from T.congolense STIB 68-F, which was isolated from a 7-year-old female lion on the Serengeti in 1971, after passage in a rat for 28 days, it was passaged in mice for a total of 234 days, then put through G. morsitans, then mice again (26 days), then cloned (1 tryp per mouse). STIB 68-Q was one of the clones isolated after 20 days passage in irradiated ICR mice (6 Nov 1975) Alignment of the C-terminal 60 aa of human apoL-I with baboon apoL-I and the human/baboon apoL-I chimeras. Amino acid characteristics are represented as follows, Italics: hydrophobic residues (A, F, G, I, L, P, V, W, and Y); red: basic residues (K, R, and H); green: acidic residues (D and E); blue: hydrophilic residues (N, Q, S, T) and cysteine in plain text. Asterisks denote amino acid differences. The PHD secondary structure prediction for human apoL-I is shown (E, extended; C, coil; H, helix). (B) Swiss-Webster mice were injected with empty plasmid (vector) or plasmids encoding human apoL-I or chimeric apoL-I. After 3 days mice were infected with 5,000 T. b. brucei-SRA (427-SRA). The survival rate of chimera 4 was significantly different from vector controls ( * , P Ͻ 0.0001), and chimeras 1-3 ( * , P ϭ 0.0183) (log-rank test). Survival of chimeras 1-3 was significantly different from vector controls ( ** , P ϭ 0.0005) (log-rank test). (C) Normal human serum (NHS) or the serum from mice transfected with empty vector, human apoL-I or chimeric apoL-I was incubated with His-tagged SRA at pH 5.8 and SRA complexes were bound to Ni-NTA agarose. apoL-I was detected in the bound fraction (bound) or in an equivalent dilution of whole serum (load) by Western blot analysis with anti-human apoL-I polyclonal IgG.
